-
May 20, 2025SanegeneBio's siRNA Drug Targeting CFB Receives Clinical Trial Approval from the NMPA for Complement-Mediated DiseasesMore
-
Mar. 07, 2025SanegeneBio Announces the Initiation of Phase II Clinical Trials for the siRNA Drug SGB-9768 Targeting C3More
-
Dec. 11, 2024Sanegene Announced First-in-Human Phase I Clinical Data for C3-Targeting siRNA Drug SGB-9768 at the 8th Complement-Based Drug Development SummitMore
-
Aug. 06, 2024SanegeneBio Announces FSD in Phase I Clinical Trial of SGB-9768More
-
Aug. 02, 2024SanegeneBio and Innovent Announce FPD in a Phase 1 Clinical Trial of SGB-3908More
-
Jul. 09, 2024SanegeneBio's two siRNA drugs were approved for clinical trial in ChinaMore
-
May 08, 2024The clinical trial application of an siRNA drug developed by SanegeneBio and Innovent for the treatment of hypertension has been accepted by the CDEMore
